6Robinson M. Medical therapy of inflammatory bowel disease for the 21st century. Eur J Surg Suppl, 1998, (582) :90-98.
7Podolsky DK. Inflammatory bowel disease: medical progress. N Engl J Med, 2002,347:417-429.
8Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease:a 30-year review.Gut, 2002,50:485-489.
9Stack WA, Long RG, Hawkey CJ. Short and long-term outcome of patients treated with cyclosporin for severe acute ulcerative colitis. Aliment Pharmacol Ther, 1998, 12:973-978.
10Fellermann K, Ludwig D, Stahl M, et al. Steroid unresponsive acute attacks of inflammatory bowel disease: irmnunonaodulation by tacrolimus (FK506). Am J Gastroenterol, 1998,93 : 1860-1866.
5Baudet A, Rahmi G, Bretagne A L, et al. Severe ulcerative colitis : present medical treatment strategies [ J ]. Expert Opin Pharmacother, 2008,9 ( 3 ) :447-471.
6Aratari A, Papi C, Clemente V, et al. Colectomy rate in acute ulcera- tion collitis in infliximab era [ J ]. Dig Liver Dis, 2008,40 ( 10 ) : 821 - 826.
7Danese S,Saur M, de - la Motte C, et al. Angiogenesis as a novel component of inflammatory bowel disease pathogenesis [ J ]. Gastroenterology,2006,130 (7) :2060-2073.
8Scaldaferri F, Vetrano S, Sana M, et al. VEGF A links angiogenesis and inflammation in inflammatory bowel disease pathogenesis [ J ]. Gastroenterology, 2009,136 ( 2 ) : 585-595.
9Gardiner K R,Dasari B V M. Operative management of small bowel Crohn' s disease[ J]. Surg Clin N Am,2007,87 (3) :587-610.
10Bernstein M, Irwin S, Grunberg G R. Maintenance infliximab treat- ment is associated with improved bone mineral density in crohn' s disease [ J ]. Am J Gastroentem1,2005,100 ( 9 ) :2031-2035.
